Business Genre
Long Business Description
Immunovaccine - CEO
1344 Summer Street
Suite 412
Halifax, NS B3H 0A8
Marc Mansour holds a Ph.D. in biology and has completed a Master of Business Administration. He is an expert in vaccinology and cancer immunotherapy. Since he joined Immunovaccine, Dr. Mansour led the clinical development of the DepoVax™ platform and the Company’s lead therapeutic cancer vaccine DPX-Survivac, soon entering randomized Phase II trials in ovarian cancer and glioblastoma. He represents the company to the investor and scientific communities. He continues to lead the internal development of vaccines based on the DepoVax™ platform, and externally with collaborators and commercial partners.
You are not currently logged in. Please login or register first. When registering, you will receive an activation email. Be sure to check your spam if you don't see it in your email within 60 minutes.